Viking Therapeutics Inc VKTX shares are trading higher Monday, in sympathy with Madrigal Pharmaceuticals Inc MDGL, which announced a successful trial of resmetirom for nonalcoholic steatohepatitis (NASH) and liver fibrosis.
What Happened: Madrigal highlighted positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom. Madrigal said MAESTRO-NASH achieved both liver histological improvement endpoints that the FDA proposed as reasonably likely to predict clinical benefit.
Madrigal intends to file a new drug application seeking accelerated approval of resmetirom for the treatment of non-cirrhotic NASH with liver fibrosis.
Viking Therapeutics could be viewed as a potential buyout candidate following the strong Phase III trial results from Madrigal. Viking’s VK2809 belongs to the same family of medications as resmetirom.
See Also: Madrigal Shares Skyrocket After Successful NASH Study
VKTX Price Action: Viking Therapeutics is making new 52-week highs on Monday.
The stock was up 46.2% at $5.88 at time of publication, according to Benzinga Pro.
Photo: Konstantin Kolosov from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
